• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

UAE approves Sinopharm’s protein-based vaccine

ExpressPharmaDecember 29, 2021

Tag: UAE , Sinopharm , Vaccine

The United Arab Emirates (UAE) has approved emergency use of Sinopharm’s protein-based COVID-19 vaccine and it will be available to the public as a booster dose starting January 2022, the health ministry said.

The vaccine will be produced and distributed by a joint venture between the UAE’s Group 42 and China National Biotec Group (CNBG), a unit of China National Pharmaceutical Group (Sinopharm), the ministry said in a statement on state media yesterday.

The approval came following a UAE-based study that included individuals who were previously vaccinated with two doses of Sinopharm CNBG’s inactivated vaccine, the ministry added.

Previous:Stopping dementia at the nose with combination of rifampicin and resveratrol

Next:Chinese mainland reports 182 locally transmitted COVID-19 cases

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

UAE approves Sinopharm’s protein-based vaccine | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Freeze-Dried Live Attenuated Varicella Vaccine

Freeze-Dried Live Attenuated Varicella Vaccine
2019-nCoV Vaccine(Vero Cells),Inactivated

2019-nCoV Vaccine(Vero Cells),Inactivated
Animal Vaccine Filling Line

Animal Vaccine Filling Line
Polyvalent Pneumococcal Polysaccharide Vaccine

Polyvalent Pneumococcal Polysaccharide Vaccine
Poultry Vaccine Series

Poultry Vaccine Series
Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains
Recombinant Hepatitis B Vaccine(Saccharomyces Cerevisiae)

Recombinant Hepatitis B Vaccine(Saccharomyces Cerevisiae)
liquaemin

liquaemin
Human Vaccine

Human Vaccine
Swine Vaccine Series

Swine Vaccine Series

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service